Table 1: Univariate analysis of the demographics and baseline characteristics of 241 RA patients.

Achieved SDAI 50 Did not achieve SDAI 50 P
(Group A) (Group B)
n 139 102
Age (years) 60 (43-68) 57 (46-68) 0.946*
Sex (female, %) 82 85 0.616**
Disease duration (year) 4 (2-9) 4 (1-11) 0.370*
Smoking history (yes, %) 22 35 0.038**
Body mass index 21 (20-24) 21 (19-24) 0.537*
Biological agent (naïve, %) 78 68 0.083**
Steroid dosage (mg/d) 2 (0-5) 2 (0-5) 0.905*
MTX dosage (mg/w) 8 (6-10) 8 (6-12) 0.105*
Combined csDAMRDs (yes, %) 17 16 0.880**
ESR (mm/H) 38 (16-67) 21 (12-51) 0.008*
CRP (mg/dL) 1 (0.29-3.74) 1 (0.143-2.643) 0.053*
RF (mg/dL) 64 (18.825-197.95) n=134 56 '26.35-135.15) n=99 0.381*
MMP-3 (ng/mL) 150 (74.9-312.4) n=132 140 (64-309) n=100 0.979*
TJC 7 (4-11) 6 (2.25-10) 0.178*
SJC 4 (2-8) 3 (1-6) 0.038*
PTGA 53 (31-74.5) 55 (28-70.75) 0.519*
PHGA 65 (32-76) 48 (22.25-72) 0.020*
SDAI 26 (17-35) 18 (11-28) n=126 0.006*
HAQ-DI 0 (0.125-1) n=137 1 (0.09375-1.125) n=96 0.281*
SF-36 PCS 30 (21-39) n=103 30 (21-40) n=80 0.682*
MCS 50 (44-54) n=103 49 (44-55) n=80 0.791*
RCS 45 (31-56) n=103 45 (32-57) n=80 0.824*

MTX, methotrexate
csDMARD, conventional synthetic disease-modifying antirheumatic drugs
RF, rheumatoid factor
MMP-3, matrix metalloproteinase 3
SDAI, simplified disease activity index
TJC, tender joint count
SJC, swollen joint count
PTGA, patient’s global assessment
PHGA, evaluator's global assessment
HAQ-DI, health assessment questionnaire disability index
SF-36, short form-36.
PCS, physical component summary score
MCS, mental component summary score
RCS, role/social component summary score
*analysis using MannWhitney U test
**analysis using chi-squared test for independence